Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter phase 4 study of arginine acetate for immune function support in trauma, burn, and gastrointestinal tumor surgery patients
ChiCTR-TRC-11001717Phase 4Completed
- Sponsor
- Army Specialized Medical Center
- Start
- Nov 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of arginine in Physical trauma, burn injury and gastrointestinal neoplasia (2 arms), sponsored by Army Specialized Medical Center. Primary endpoints: NK cell population, CD4/CD8 ratio and 5 more. Started Nov 2014; status: completed.
02
Drugs
arginine
03
Conditions
Physical traumaburn injurygastrointestinal neoplasia
Beyond the preview
Go deeper on ChiCTR-TRC-11001717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001717.